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Introduction
Molecular biomarker analysis for the personalised treatment
of non-small cell lung cancer (NSCLC) and colorectal cancer
(CRC) is becoming more common, due to the number and
availability of molecular targets for predictive biomarker test-
ing increasing [1]. Clinical laboratories must implement
accurate test procedures and provide timely and reliable test
results, to ensure that appropriate therapies are administered to
patients [2]. The challenge for laboratories is to keep pacewith
molecular biomarker developments while maintaining excel-
lence in service standards.
Plasma circulating tumour DNA (ctDNA) may be found in
the blood of cancer patients, alongside a larger fraction of circu-
lating free DNA (cfDNA). Plasma ctDNA testing is becoming
more common in the management of cancer patients [3]. It has
several advantages: in the absence of suitable or sufficient tissue
biopsy, it yieldsmaterial for molecular analysis, can demonstrate
molecular resistance to targeted treatment and is an alternative to
invasive tissue sampling [4]. Plasma ctDNA analysis may also
prove useful in cases of intra- and inter-tumour heterogeneity
[5].With formal approval from the European Medicine Agency
(EMA), several clinical applications for plasma ctDNA testing
are now being considered, including the detection of Epidermal
Growth Factor Receptor (EGFR) mutations in the plasma of
patients with advanced NSCLC [6].
The implementation of new methods such as plasma
ctDNA testing can be challenging for diagnostic laboratories.
Indeed, it has been shown that inexperience in specialised and
complex techniques can compromise the result quality [2, 7].
To address these issues, four EQA providers came together
under the umbrella organisation the International Quality
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Network for Pathology IQN Path (IQN Path): Association
Italiana di Oncologia Medica (AIOM), European Molecular
Genetics Quality Network (EMQN), European Society of
Pathology (ESP) EQA and the United Kingdom National
External Quality Assessment Service (UK NEQAS) for
Molecular Genetics. Their aim was to survey testing methods
currently in use and to pilot an EQAwhich assessed the stan-
dards of plasma ctDNA testing. This article summarises the
results of the survey, which evaluated current laboratory prac-
tices in this field and which will subsequently inform the de-
sign of a pilot EQA scheme for plasma ctDNA testing.
Methods
An online survey of plasma ctDNA testing practice was de-
signed by the IQN Path collaborative group. The survey was
circulated by the four EQA members to their global network
of participants, EMQN (1480), UK NEQAS (500), AIOM
(47) and ESP testing schemes (568). The survey comprised
six sections which included questions about laboratory partic-
ipation in EQA for solid tumour testing in NSCLC and CRC,
current experience and technologies used in plasma ctDNA
testing and any analytical limitations of current test method-
ologies. The survey opened for completion between February
2016 and the middle of March 2016. The responses were
analysed to understand current practices in the field of
EGFR and RASmutation testing using ctDNA and will inform
design of future pilot EQA scheme.
Results
Completed surveys were received from 167 laboratories. The
submitted data was collated and summarised.
The survey showed that some form of ctDNA plasma testing
for EGFR, KRAS and NRAS was used in the majority of
responding laboratories (151/167, 90%) but that only 62 (37%)
laboratories currently perform diagnostic plasma ctDNA testing
(Fig. 1). A further 56 laboratories (34%) have plasma ctDNA test
methodologies in the development phase (Fig. 1). During 2015,
46 diagnostic laboratories tested fewer than 100 samples, while 9
tested more than 101 samples (4 did not respond).
The most frequently used method for plasma ctDNA testing
was next-generation sequencing (NGS), used by 27% of labora-
tories. The most commonly used testing platform was Ion PGM
System®/Thermo Fisher Scientific (Fig. 2a). After NGS, the
most frequently used methods were Roche cobas®, Qiagen
therascreen® and ddPCR (Fig. 2a). Of the ddPCR assays,
BioRad’s QX 200 ddPCR assays were the most commonly used
(Fig. 2a).
Of the laboratories using more than one plasma ctDNA test-
ing method, 90 (54%) employ a single method, 51 (31%) use
two and 8 (5%) use three different methods. The remaining 18
did not provide methodology information. Figure 2b illustrates
the diversity of methods currently employed in plasma ctDNA
testing.
The stated limit of detection (LoD) of all allele frequencies
for all laboratories was below 20%. The LoD was 5–20% in
13 laboratories (7.8%), < 5% in 56 laboratories (33.5%) and
< 1% in 62 laboratories (37.1%). The remaining laboratories
did not provide any LoD data (21.6%). Most laboratories
performing NGS (97.8%) provided an LoD level of < 5%
(44.2%), < 1% (53.8%) and 1% (< 5%). The other laboratories
stated an LoD level of > 20% or provided no data. For ddPCR,
65.6% of laboratories gave an LoD of < 1 and 21.8% stated an
LoD between 1 and < 5%. A single laboratory stated an LoD
of < 10% and the remaining 3 offered no data.
The EGFR, KRAS and NRAS mutations targeted for analy-
sis in plasma samples were collected. The three most common
targets for each gene are outlined in Table 1.
Discussion
Current practice for plasma ctDNA testing in CRC and
NSCLC tumour diagnostic testing was examined by the sur-
vey. The laboratories offering plasma ctDNA testing were
Total sent: 167
No test: 14 (8%)











Fig. 1 Summary of the survey results of EGFR, KRAS and NRAS
mutation testing in plasma samples. Figures reported are based on the
number of laboratories offering testing for either research or diagnostic
use or have testing in the development phase. Note: some laboratories use
testing for more than one purpose as may be seen by the intersections in
the Venn diagram
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those which already provide tissue-basedmolecular pathology
services. Most survey participants (86.8%) offered diagnostic
testing of EGFR, KRAS and NRAS from formalin-fixed paraf-
fin-embedded (FFPE) tissue and participated in EQA for solid
tumours. Of these, 78% participated in EQA assessment for
NSCLC and 68% for CRC, so these laboratories already have
experience in molecular technologies and understand how to
interpret and report results.
The data suggest that no single, definitive technology
for the analysis of plasma ctDNA has yet emerged. The
methods currently used are a mixture of commercial and
locally developed assays. These assays must be
optimised and validated: they must also support
adequate test sensitivity and available starting material
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Fig. 2 The breakdown of
methodologies used for mutation
testing in plasma samples. Values
represent the number of
laboratories running a specific
platform. Some laboratories use
more than one testing method. a
The current methods used for
plasma ctDNA mutation testing
by number of laboratories (%
included). b A detailed
breakdown of methods specified
as Bother testing methods^
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Plasma ctDNA is present at low quantities, mixed within
circulating free DNA (cfDNA) in the blood. Therefore, in
order to have confidence in the results of plasma ctDNA test-
ing, attention must be paid to the assay sensitivity. However,
the optimal sensitivity for ctDNA testing is not yet clear.
An example of a specific clinical application of plasma
ctDNA is the phase IV EGFR tyrosine kinase inhibitor
Gefitinib ‘Follow Up Measure’ trial that facilitated the ap-
proval of plasma ctDNA testing for EGFR in NSCLC patients
(6). The trial showed that although the Qiagen therascreen®
kit had a low sensitivity (65.7%), it had a good correlation
with the response of patients to first-line treatment with
Gefitinib [4].
In the future, more sensitive techniques are likely to detect
more patients with EGFR mutations and may also identify
EGFR variants in patients with heterogeneous expression [8].
The use of highly sensitive ctDNA testing methods has
permitted new insights into heterogeneity, e.g. p.T790M mu-
tations in the ctDNA of patients with a tumour mass that tested
negative for the resistance mutation [9]. Patients with positive
plasma ctDNA tests and negative tissue results had shorter
progression-free survival compared to patients with EGFR
p.T790M detected in both their tumour tissue and plasma
ctDNA [9]. In the future, accurate measurements of the ratio
of resistant EGFR mutations to sensitising mutations might
help select patients who are more likely to benefit from treat-
ment with drugs targeting p.T790M [10].
Similarly, NGS panels may be used to determine the rela-
tive abundance of a tumour variant to support individually
tailored therapy. Where NGS is used, a broad range of
molecular targets may be detected simultaneously; however,
this may be at the cost of lower test LoD. Non-NGS-based
methods may provide greater sensitivity but have the limita-
tion of assaying fewer molecular targets.
There is a significant interest in the development of
plasma ctDNA services. However, despite the 2014 EMA
approval for plasma ctDNA biopsies which determine the
suitability of first-line treatment of NSCLC with Gefitinib,
few laboratories currently deliver NSCLC or CRC clinical
diagnostic services [11]. For plasma ctDNA testing to be-
come integrated into routine practice, those offering clini-
cal services must be educated on its applications.
However, until local services can validate and embed test-
ing in patient pathways, laboratory and clinical uptake of
plasma ctDNA may be hindered.
Current clinical applications for ctDNA are largely con-
fined to NSCLC and CRC, although there is potential for its
use in many other areas of oncology. Laboratories must pro-
vide high-quality testing services in which clinical teams and
patients have confidence. The delivery of National and
International EQA schemes is essential to maintain quality
through the standardisation of sample logistics, molecular as-
says and result interpretation, as well as playing an important
role in supporting education [4].
As many laboratories plan to implement the testing of plas-
ma ctDNA, it is clear that support from well-designed EQA
schemes is needed. Without this support, laboratories may be
slower to offer plasma ctDNA clinical services or may en-
counter issues. Surveying current practices and collecting data
to inform EQA design is a task that may be harmonised be-
tween several EQA providers, all with the aim of increasing
efficiencies and supporting best practice standards in quality
assessment [12].
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Table 1 Tabulated frequency of the genes and variants analysed by
laboratories for ctDNA testing
Gene Target Number of
laboratory
responses
EGFR All variants within specified exons 61
p.(G719A), p.(G719C), p.(G719S),
p.(S768I), p.(T790M), p.(L858R),
p.(L861Q), deletions in exon 19
and insertions in exon 20
28
p.(T790M), p.(L858R) and deletions
in exon 19
27
KRAS All variants within specified exons 62




p.(G12D), p.(G12R), p.(G12A), p.(G12C),
p.(G12S), p.(G12V) and p.(G13D)
11
NRAS All variants within specified exons 57
p.(G12D), p.(Q61K), p.(Q61R), p.(Q61L)
and p.(Q61H)
10
All variants in codons 12, 13, 59, 117 and
146
4
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